$0.75
4.73% today
Nasdaq, Apr 03, 07:49 pm CET
ISIN
US74065P1012
Symbol
PRLD
Sector
Industry

Prelude Therapeutics Inc Stock price

$0.79
+0.10 15.09% 1M
-1.24 61.22% 6M
-0.49 38.26% YTD
-3.83 82.96% 1Y
-6.76 89.57% 3Y
-18.21 95.86% 5Y
-18.21 95.86% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.02 2.19%
ISIN
US74065P1012
Symbol
PRLD
Sector
Industry

Key metrics

Market capitalization $53.53m
Enterprise Value $-62.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.60
EV/Sales (TTM) EV/Sales -8.86
P/S ratio (TTM) P/S ratio 7.65
P/B ratio (TTM) P/B ratio 0.33
Revenue (TTM) Revenue $7.00m
EBIT (operating result TTM) EBIT $-139.71m
Free Cash Flow (TTM) Free Cash Flow $-103.65m
Cash position $133.61m
EPS (TTM) EPS $-1.82
P/E forward negative
Short interest 12.90%
Show more

Is Prelude Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Prelude Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Prelude Therapeutics Inc forecast:

1x Buy
50%
1x Sell
50%

Analyst Opinions

2 Analysts have issued a Prelude Therapeutics Inc forecast:

Buy
50%
Sell
50%

Financial data from Prelude Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
7 7
-
100%
- Direct Costs 1.77 1.77
13% 13%
25%
5.23 5.23
356% 356%
75%
- Selling and Administrative Expenses 25 25
2% 2%
360%
- Research and Development Expense 118 118
14% 14%
1,686%
-138 -138
6% 6%
-1,971%
- Depreciation and Amortization 1.77 1.77
13% 13%
25%
EBIT (Operating Income) EBIT -140 -140
6% 6%
-1,996%
Net Profit -127 -127
4% 4%
-1,817%

In millions USD.

Don't miss a Thing! We will send you all news about Prelude Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prelude Therapeutics Inc Stock News

Neutral
GlobeNewsWire
24 days ago
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and esophageal cancer
Neutral
GlobeNewsWire
29 days ago
WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.
Neutral
GlobeNewsWire
4 months ago
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy
More Prelude Therapeutics Inc News

Company Profile

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Head office United States
CEO Krishna Vaddi
Employees 131
Founded 2016
Website www.preludetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today